secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001437749-23-030940
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia Q3 net loss narrows to $2.6M; CardiAMP HF trial paused after DSMB review
--------------------------------------------------------------------------------

- Q3 2023 revenue $357K (up 68% YoY); net loss $2.6M improves from $3.1M YoY.
- DSMB recommended pause of CardiAMP HF trial; management agrees primary endpoint unlikely with current design.
- Subset analysis: NT-proBNP>500 patients showed 59% relative risk reduction in mortality (p=0.028).
- Company submitted new protocol (CardiAMP HF II) to FDA targeting responders; Japan PMDA consultation set for Nov 21.
- Cash used in operations $2.4M; anticipates two Helix licensing/development partnerships in Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774923030940/0001437749-23-030940-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774923030940/bcda20231107_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-030940

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer